Author + information
- Luc Van Gaal,
- Tim Garvey,
- Lawrence Leiter,
- Ujjwala Vijapurkar,
- James List,
- Robert Cuddihy,
- Jimmy Ren and
- Michael Davies
Background: Type 2 diabetes mellitus (T2DM) and obesity are pro-inflammatory states that are associated with increased cardiovascular disease (CVD) risk. Canagliflozin (CANA), an SGLT2 inhibitor, lowered A1C and weight via reduced fat mass vs glimepiride (GLIM) in a 52-wk study of patients with T2DM on metformin. In this study, serum leptin was reduced and adiponectin was increased with CANA 300 mg vs GLIM. Limited data exist on the effect of SGLT2 inhibition on inflammatory markers and chemokines associated with CVD. This post hoc analysis evaluated select biomarkers in patients receiving CANA or GLIM.
Methods: Biomarkers were assessed in a randomly selected cohort of patients on CANA 300 mg (n = 100) or GLIM (n = 100) with serum samples at baseline and 52 wks. IL-6 and TNFα were measured with ultra high-sensitivity assays (Simoa-Quanterix); CRP, PAI-1, VCAM-1, and MCP-1 were measured using a multiplex assay (Myriad RBM).
Results: At Wk 52, median serum IL-6 was ∼23% lower with CANA vs GLIM. Change in IL-6 was not correlated with changes in A1C, weight, or lipids. A small increase in serum TNFα (9%) was seen with CANA vs GLIM. No between-treatment differences were observed with the other biomarkers.
Conclusions: CANA 300 mg decreased serum IL-6 with a small increase in TNFα and neutral effects on other biomarkers vs GLIM in T2DM patients. These results coupled with previously observed effects on leptin and adiponectin with CANA suggest improved adipose tissue function, which may lead to improved cardiometabolic health.
Moderated Poster Contributions
Prevention Moderated Poster Theater, Poster Hall, Hall C
Saturday, March 18, 2017, 12:30 p.m.-12:40 p.m.
Session Title: The Intersection of Diabetes and ASCVD
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1222M-03
- 2017 American College of Cardiology Foundation